Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Daewoong takes 30.2% stake in fellow Korean pharmaco HanAll

Executive Summary

Daewoong Pharmaceutical Co. Ltd. acquired a 30.2% stake in HanAll Pharmaceutical Co. Ltd. Daewoong paid $94.1mm (KRW104.6bn) for 15.5mm HanAll shares (consisting of 6mm existing shares owned by HanAll chairman Kim Byung-tae and 9.5mm new shares through a rights offering), implying a $6.07 per-share price (an 8% discount).

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Generic Drugs
    • OTC, Consumer
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity

Related Companies